Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients

Rheumatoid arthritis (RA) patients are currently treated with biological agents mostly aimed at cytokine blockade, such as tumor necrosis factor-alpha (TNFα). Currently, there are no biomarkers to predict therapy response to these agents. Here, we aimed to predict response to adalimumab (ADA) treatm...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Frontiers in immunology Ročník 14; s. 1303231
Hlavní autori:	Hageman, Ishtu, Mol, Femke, Atiqi, Sadaf, Joustra, Vincent, Sengul, Hilal, Henneman, Peter, Visman, Ingrid, Hakvoort, Theodorus, Nurmohamed, Mike, Wolbink, Gertjan, Levin, Evgeni, Li Yim, Andrew Y.F., D’Haens, Geert, de Jonge, Wouter J.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland Frontiers Media S.A 22.12.2023
Predmet:	adalimumab Adalimumab - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Biomarkers DNA methylation Epigenome Humans Immunology machine learning rheumatoid arthritis therapy response Tumor Necrosis Factor-alpha DNA methylation machine learning rheumatoid arthritis therapy response adalimumab
ISSN:	1664-3224, 1664-3224
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!